Rezolute - Common (Nv) (RZLT) closed at $3.66 on November 13, 2026, down 5.6% from the previous close, on volume of 4,859,970 shares (30-day average 1,454,836).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Call Spread | 15-Jan-272.5 : 10 C | 1,758 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Rezolute Reports Phase 3 upLIFT Success With 13 of 16 Responders in Tumor Hyperinsulinism
Market Chameleon (Fri, 13-Nov 4:53 AM ET)
Rezolute releases interim phase 3 results of ersodetug in tumor hyperinsulinism
Seeking Alpha News (Fri, 13-Nov 8:49 AM ET)
Rezolute Reports Positive Preliminary Phase 3 Ersodetug Results
TipRanks (Fri, 13-Nov 6:48 AM ET)
Rezolute prices $100M public offering of common stock and pre-funded warrants
Seeking Alpha News (Fri, 13-Nov 6:25 AM ET)
Globe Newswire (Fri, 13-Nov 6:19 AM ET)
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Globe Newswire (Fri, 13-Nov 6:18 AM ET)
Rezolute’s Buy Rating and $14 Price Target Unchanged Ahead of Phase 3 Tumor Hyperinsulinism Readout
TipRanks (Tue, 10-Nov 5:35 PM ET)
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Rezolute to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 7:30 AM ET)
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Rezolute - Common (Nv) trades on the NASDAQ stock market under the symbol RZLT.
As of November 13, 2026, RZLT stock price declined to $3.65 with 4,859,970 million shares trading.
RZLT has a beta of 1.30, meaning it tends to be more sensitive to market movements. RZLT has a correlation of 0.01 to the broad based SPY ETF.
RZLT has a market cap of $353.52 million. This is considered a Small Cap stock.
In the last 3 years, RZLT traded as high as $11.46 and as low as $.72.
The top ETF exchange traded funds that RZLT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
RZLT has underperformed the market in the last year with a price return of -63.2% while the SPY ETF gained +13.4%. RZLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.5% and -7.5%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
RZLT support price is $3.67 and resistance is $4.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RZLT shares will trade within this expected range on the day.